MYSEC-PM scoring (secondary MF)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-07-01 — Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis.: Large MYSEC-cohort NGS study shows that augmenting MYSEC-PM with ASXL1 + UTS (U2AF1/TP53/SRSF2) mutations (MYSEC-mPM), and optionally complex/monosomal karyotype (MYSEC-kmPM), significantly improves OS prediction in post-PV/post-ET MF, suggesting molecular refinement should accompany clinical MYSEC-PM when timing transplant referral. (novelty: 3)
Open questions
Related
Contributing findings
Precision medicine in myelofibrosis: from molecular profiling to personalized therapy.
15-jul-2026
novelty 2
per-area 3
strengthens
Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis.
01-jul-2026
novelty 3
per-area 4
strengthens